Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

被引：16
|
作者：
Modi, S. [1 ]
Jacot, W. [2 ]
Iwata, H. [3 ]
Park, Y. H. [4 ]
Vidal Losada, M. J. [5 ]
Li, W. [6 ]
Tsurutani, J. [7 ]
Zaman, K. [8 ]
Ueno, N. T. [9 ]
Prat, A. [10 ]
Papazisis, K. [11 ]
Rugo, H. S. [12 ]
Harbeck, N. [13 ]
Im, S-A. [14 ]
De Laurentiis, M. [15 ]
Orbegoso, C. M. A. [16 ]
Yung, L. [17 ]
Cheng, F-C. [18 ]
Cheng, Y. [19 ]
Cameron, D. A. [20 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[2] Inst Canc Montpellier, Med Oncol, Montpellier, France
[3] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan
[4] Samsung Med Ctr, Hematol Oncol, Seoul, South Korea
[5] Hosp Clin Barcelona, Oncol Med, Barcelona, Spain
[6] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China
[7] Showa Univ, Adv Canc Translat Res Inst, Shinagawa, Japan
[8] Lausanne Univ Hosp CHUV, Oncol, Lausanne, Switzerland
[9] Univ Hawaii, Med, Ctr Canc, Honolulu, HI USA
[10] August Pi & Sunyer Biomed Res Inst IDIBAPS, Med Oncol, Translat Genom & Targeted Therapies Grp, Barcelona, Spain
[11] Euromed Gen Clin, Oncol, Thessaloniki, Greece
[12] UCSF, Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[13] LMU Univ Hosp, Breast Ctr, Obstet & Gynecol, Munich, Germany
[14] Seoul Natl Univ, Seoul Natl Univ Hosp, Internal Med, Coll Med, Seoul, South Korea
[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Breast Oncol Unit, Naples, Italy
[16] Daiichi Sankyo Inc, Global Oncol Res & Dev, Rueil Malmaison, France
[17] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA
[18] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[19] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA
[20] Univ Edinburgh, Edinburgh Univ Canc Ctr, Edinburgh, Midlothian, Scotland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376O
引用
收藏
页码：S334 / S335
页数：2
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joohyuk
    Vidal, Maria
    Tokunaga, Eriko
    Tsurutani, Junji
    Ueno, Naoto T.
    Chae, Yee Soo
    Lee, Keun Seok
    Niikura, Naoki
    Park, Yeon Hee
    Wang, Xiaojia
    Xu, Binghe
    Gambhire, Dhiraj
    Yung, Lotus
    Meinhardt, Gerold
    Wang, Yibin
    Harbeck, Nadia
    Cameron, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [2] Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
    Ueno, N. T.
    Jacot, W.
    Yamashita, T.
    Sohn, J.
    Tokunaga, E.
    Prat, A.
    Tsurutani, J.
    Park, Y. H.
    Rugo, H. S.
    Xu, B.
    Cardoso, F.
    Mitri, Z.
    Mahtani, R.
    Dunton, K.
    Wang, Y.
    Gambhire, D.
    Cottone, F.
    Harbeck, N.
    Cameron, D. A.
    Modi, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S632 - S633
  • [3] Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)
    Tsurutani, J.
    Jacot, W.
    Yamashita, T.
    Riaz, F.
    Yerushalmi, R.
    Im, S-A.
    Niikura, N.
    Halser-Strub, U.
    Cortes, J.
    Wennstig, A-K.
    Chae, Y.
    Wang, X.
    Li, W.
    Simon, H.
    Masci, G.
    Tamburini, E.
    Aguilar, C. Orbegoso
    Tecson, K.
    Yung, L.
    Modi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S342 - S343
  • [4] Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR plus ) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04
    Modi, Shanu
    Niikura, Naoki
    Yamashita, Toshinari
    Jacot, William
    Sohn, Joohyuk
    Tokunaga, Eriko
    Vidal, Maria Jesus
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yeesoo
    Ueno, Naoto T.
    Prat, Aleix
    Suto, Fumitaka
    Kuwahara, Yusuke
    McEwen, Robert
    Feng, Wenqin
    Goto, Hiroki
    Orbegoso, Cecilia
    Cameron, David A.
    Tsurutani, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04
    Tsurutani, Junji
    Modi, Shanu
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Wang, Xiaojia
    Li, Wei
    Im, Seock-Ah
    Xu, Binghe
    Lu, Yen-Shen
    Gambhire, Dhiraj
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1379 - S1379
  • [6] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Tokunaga, Eriko
    Niikura, Naoki
    Park, Yeon Hee
    Lee, Keun Seok
    Chae, Yee Soo
    Xu, Binghe
    Wang, Xiaojia
    Im, Seock-Ah
    Li, Wei
    Lu, Yen-Shen
    Aguilar, Cecilia Orbegoso
    Nishijima, Soichiro
    Nishiyama, Yuji
    Sugihara, Masahiro
    Modi, Shanu
    Tsurutani, Junji
    BREAST CANCER, 2024, 31 (05) : 858 - 868
  • [8] Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Tarantino, P.
    Tolaney, S. M.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 949 - 950
  • [9] Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04
    Ueno, N. T.
    Niikura, N.
    Yamashita, T.
    Jacot, W.
    Cameron, D. A.
    Tsurutani, J.
    Sohn, J.
    Tokunaga, E.
    Vidal Losada, M. J.
    Park, Y. H.
    Lee, K. S.
    Chae, Y. S.
    Prat, A.
    Suto, F.
    Kuwahara, Y.
    Boran, A. D.
    Kobayashi, M.
    Kumar, V.
    Aguilar, C. Orbegoso
    Modi, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S401 - S402
  • [10] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
12345